StreetAlpha.app
Home › Stocks › EIKN

Eikon Therapeutics, Inc. (EIKN)

Healthcare
$4.74
▼ −0.42%
LAST CLOSE · NOV 20

Eikon Therapeutics develops cancer medicines, with its most advanced candidate in Phase 2/3 trials for melanoma. It last closed at $4.74 on Nov 20, down 0.42% on the day. The next earnings report for EIKN is expected around Mon, Mar 29, 2027. For the quarter ended Sep 2026, EIKN reported EPS of -$1.59. Over its last 4 reports the stock moved an average of 8.4% the session after earnings. Over the last 12 months EIKN insiders bought $52.2M of stock on the open market and sold $0, according to SEC Form 4 filings.

AI Auto Pilots
Is EIKN in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold EIKN.
Next report
Mar 29
Estimated date · Time not announced
Reported EPS
-$1.59
Quarter ended Sep 2026
Year ago EPS
—
Same quarter last year
Revenue
—
Last reported quarter
Estimates and implied move
Consensus forecasts and the move options price in
How EIKN moved after its last 4 reports
Average move the session after a report ±8.4%
Nov 12, 2026Time not announced−9.4%
Aug 13, 2026After the close+7.0%
May 11, 2026After the close+15.9%
Mar 30, 2026Time not announced−1.3%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on EIKNStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on EIKN
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on EIKN

Technical Analysis

EIKN · as of the Nov 20 close · updated each morning
Downtrend, nearing oversold

The stock is 19% below its 20 day and 48% below its 50 day average. It is 112% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 33), near oversold. The nearest support is the 52 week low at $4.72, and the nearest resistance the Pivot at $4.89.

Short trendBearish
Long trendBearish
MomentumWeak
StretchNear oversold
VolatilityHigh, 13.3%/day
Key levels
$17.4052 week high+267.1%
$10.05200 day average+112.0%
$8.72100 day average+84.0%
$7.0250 day average+48.1%
$6.43Swing high (Nov 5)+35.7%
$5.6320 day average+18.8%
$5.04Pivot R1+6.3%
$4.89Pivot+3.2%
$4.74Last close
$4.7252 week low−0.4%
$4.59Pivot S1−3.2%
Indicators
RSI (14)32.93Weak, oversold below 30Neutral
MACD-0.59Below its signal lineBearish
Stochastic4.9Near the bottom of its rangeOversold
ADX (14)20.5Weak trend
Williams %R-99.0Oversold below −80, overbought above −20Oversold
CCI (20)-147.6Oversold below −100, overbought above 100Oversold
Rate of change−19.7%Change over 10 sessionsBearish
ATR (14)$0.63Typical daily range, 13.3% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for EIKN

What happened before

See how EIKN did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Whale Options Flow

90D
Whale options flow for EIKNHow many large options trades hit EIKN, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

EIKN Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Strongly bullish
Strongly bearishNeutralStrongly bullish
  • ▲75 buying vs 17 selling
  • ▲Held by funds +9.6 pts
  • ▲Funds holding +21
  • ▲Superinvestors: 2 added, 1 cut
  • ●Put/call not meaningful
Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding9877+27.3%
In funds' top 1045−20.0%
Held by funds58.5%48.9%+9.6 pts
New / increased30 / 4537 / 17+38.9%
Reduced / sold out8 / 99 / 12−19.0%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See EIKN institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

EIKN Insider Trading

All filings →
Insider trading · 12 months
Insiders are net buyers
Bought$52.2M6 buys · 6 insiders
Sold$00 sales · 0 insiders
Cluster buy: 5 insiders bought $51.1M between Feb 4 and Feb 6.
2026-02 bought $51.1M2026-09 bought $1.0MDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Sep 3Column Group IV GP, LP10% ownerBuy89,200$11.56$1.0M
Feb 6Column Group Opportunity III, LP10% ownerBuy2,117,760$18.00$38.1M
Feb 4Foresite Capital Opportunity Management V, LLC10% ownerBuy55,555$18.00$1000K
Feb 4Lux Ventures V, L.P.10% ownerBuy277,776$18.00$5.0M
Feb 4Josh WolfeDirectorBuy277,776$18.00$5.0M
Feb 4Kenneth C FrazierDirectorBuy111,111$18.00$2.0M
Every insider buy and sale for EIKN over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See EIKN insider trades →

From SEC Form 4 filings by EIKN's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether EIKN is in one of them and how their past EIKN trades turned out.

EIKN in the AI portfolios
Loading…

EIKN News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered EIKN in an article yet. Here's the latest on the wider market.

EIKN in the news

About Eikon Therapeutics

Eikon Therapeutics is a biopharmaceutical company based in Millbrae, California, that is developing medicines for cancer. Its main focus is oncology, and its most advanced candidate, EIK1001, is in Phase 2/3 trials with pembrolizumab for advanced melanoma. The company also has candidates that inhibit PARP1 for ovarian, breast, prostate and pancreatic cancers, plus an early-stage helicase inhibitor. Its medicines are still in clinical development and are not yet sold to patients.

Headquarters
Millbrae, CA